Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Frontiers in Oncology, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen +13 more
doaj +3 more sources
Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Non peer ...
Abdelhakim Salem +5 more
doaj +6 more sources
Cardiotoxic effects of angiogenesis inhibitors. [PDF]
Clin Sci (Lond), 2021 The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies.
Dobbin SJH +4 more
europepmc +7 more sources
Angiogenesis Inhibitors in Small Cell Lung Cancer [PDF]
Frontiers in Oncology, 2021 Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung ...
Agnese Montanino +14 more
doaj +3 more sources
Angiogenesis Inhibitors in NSCLC. [PDF]
Int J Mol Sci, 2017 Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor
Manzo A +10 more
europepmc +6 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]
Journal of Ovarian Research, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj +2 more sources
Journal of Hematology & Oncology, 2016 Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu +5 more
doaj +2 more sources
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma [PDF]
Frontiers in Pharmacology, 2016 Background: Angiogenesis inhibitors have become an important therapeutic approach in the treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of angiogenesis of Sorafenib in increasing overall survival of patients with HCC is ...
M. Berretta +7 more
semanticscholar +8 more sources
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma [PDF]
IJU Case Reports, 2020 Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto +8 more
doaj +2 more sources